Ivabradine as adjuvant treatment for chronic heart failure

Review of 19 studies (n=19,628) found evidence of no difference in cardiovascular mortality and serious adverse events between long‐term treatment with ivabradine and placebo/usual care/no treatment in participants with heart failure with reduced ejection fraction.

Source:

Cochrane Database of Systematic Reviews